SCIEX
At SCIEX, our mission is to deliver solutions for the precision detection and quantification of molecules, empowering our customers to protect and advance the wellness and safety of all
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
Related Content
Research & Development
Improving the analysis of RNA medicines: what to expect in 2024
In vitro transcribed (IVT) RNA development has advanced since the first messenger RNA (mRNA) vaccines to prevent COVID-19 entered the market in 2020. Now the focus of similar drug candidates is on other prophylactic vaccines to prevent infectious diseases, including influenza and respiratory syncytial virus (RSV), and therapeutic drugs that might soon be used to treat cancer and other diseases
Analysis
How self-replicating RNA can transform in vitro-transcribed drug development
In vitro-transcribed (IVT) ribonucleic acids (RNAs) are integral to next-generation nucleic acid-based drugs. The recent success of messenger RNA (mRNA)-based vaccines against COVID-19 created new opportunities to untangle their working mechanism, advantages and disadvantages. Kerstin Pohl, Senior Manager, Cell & Gene Therapy and Nucleic Acids, SCIEX, reports
Research & Development
Host cell protein analysis: strategies to improve sensitivity and reproducibility
Given that the US FDA approved 25 new cellular and gene therapy products in 2022, gene-based vaccines and therapeutics have now entered the mainstream pharmaceutical industry. However, the rising interest in gene-based strategies puts pressure on manufacturers to demonstrate optimum efficacy and safety
Analysis
Treating infection with precise medicine may prevent our next pandemic
Antimicrobial resistance (AMR) is a grave concern that the scientific and medical community have been warning the public about for decades. There have been no new antibiotics for 35 years and no truly effective incentive for drug makers to develop them, making this threat even more urgent. As the COVID-19 pandemic demonstrated, preparedness could save countless lives and the world’s economy
Ingredients
Developing innovative antivirals for novel viruses
Since the emergence of COVID-19, researchers worldwide have striven to study and overcome this new disease and the novel coronavirus (SARS-CoV-2) that causes it. To achieve this, we will probably need both vaccines and antiviral drugs, report Zamas Lam, Senior Vice President of Preclinical Development, and
John Kolman, Vice President of Translational Medicine, QPS